Search our website

Hepatitis B

Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021
June 23rd, 2021
Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
April 21st, 2021
VBI Vaccines Announces Phase 1b/2a Data and Progress of Hepatitis B Immunotherapeutic Candidate
April 12th, 2021
VBI Vaccines Announces U.S. FDA Acceptance of BLA Filing for VBI’s 3-Antigen Prophylactic Hepatitis B Vaccine
February 2nd, 2021
VBI Vaccines Announces Publication of Results from a Phase 4 Study of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine in Vaccine
January 15th, 2021
VBI Vaccines to Discuss Hepatitis B Portfolio in Virtual Fireside Chat Hosted by Raymond James
December 2nd, 2020
VBI Vaccines Announces Positive Interim Phase 1b/2a Data for Hepatitis B Immunotherapeutic in Patients with Chronic Infection
November 18th, 2020
VBI Vaccines to Present at the H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference
October 15th, 2020
VBI Vaccines and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B Infection
November 14th, 2019
VBI Vaccines Provides Corporate Update, Outlook for 2019, and Year-End 2018 Financial Results
February 25th, 2019
VBI Vaccines Enters into License and Collaboration Agreement with Brii Biosciences for up to $129 Million plus Royalties to Develop a Functional Cure for Hepatitis B
December 6th, 2018

Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI

Sign Up NowArrow
Go top